Therapeutic strategies in patients with acute myeloid leukemia (AML) have not changed significantly over the last decades. Appropriate strategies are ultimately driven by the assessment of patients' fitness to define suitability for intensive induction chemotherapy, which produces high initial remission rates but, increased likelihood of relapse. Old/unfit AML patients still represent an urgent and unmet therapeutic need. Epigenetic deregulation represents a strategic characteristic of AML pathophysiology whereby aberrant gene transcription provides an advantage to leukemic cell survival. Efforts to re-establish impaired epigenetic regulation include hypomethylating agents and histone deacetylase inhibitors (HDACi).
Morabito, F.g., Voso, M.t., Hohaus, S., Gentile, M., Vigna, E., Recchia, A., et al. (2016). Panobinostat for the treatment of acute myelogenous leukemia. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 25(9), 1117-1131 [10.1080/13543784.2016.1216971].
Panobinostat for the treatment of acute myelogenous leukemia
MORABITO, FEDERICO GIUSEPPE;VOSO, MARIA TERESA;GENTILE, MARIA;LO COCO, FRANCESCO;
2016-01-01
Abstract
Therapeutic strategies in patients with acute myeloid leukemia (AML) have not changed significantly over the last decades. Appropriate strategies are ultimately driven by the assessment of patients' fitness to define suitability for intensive induction chemotherapy, which produces high initial remission rates but, increased likelihood of relapse. Old/unfit AML patients still represent an urgent and unmet therapeutic need. Epigenetic deregulation represents a strategic characteristic of AML pathophysiology whereby aberrant gene transcription provides an advantage to leukemic cell survival. Efforts to re-establish impaired epigenetic regulation include hypomethylating agents and histone deacetylase inhibitors (HDACi).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
